Industry Voices, Analysis & Insights

When selecting partners, meeting stringent sustainability criteria along entire pharmaceutical supply chains has far-reaching environmental, economic and reputational benefits. Whilst adding a sustainability criteria to the bidding process is a positive one for driving more responsible operations across the entire pharmaceutical industry, it simultaneously amplifies the complexity of selecting a Contract Manufacturing Organization (CMO).

Unlock the report to delve into vital statistics and expert insights, covering:

• Stringent selection criteria: understand the pivotal role stringent criteria play in shaping responsible and sustainable partnerships
• Bottom line benefits: explore the tangible economic advantages that sustainable practices bring to the forefront of your pharmaceutical operations
• Technology for greener supply chains: navigate the latest innovations driving sustainability in pharmaceutical supply chains and stay ahead in the industry

Topped up with expert commentary from industry leaders: Philip Coetzee, Director CMO Management, Daiichi Sankyo and Gregory Vanderwinden, Associate Director – External Manufacturing EU, MSD.

Elevate your CMO selection process and lead the way towards a greener, more sustainable pharmaceutical future.  Access the report now.

Pharma IQ surveyed over 50 industry professionals, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation at Bayer, this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.

Download the full report now >>>

Additional benefits to downloading the full report:

• Discover where the industry is at in its Pharma outsourcing journey
• The important factors to consider when selecting a CMO
• Find out more about how to reduce your external partner footprint
• Industry results for the greatest risks of outsourcing 
• Learn more about the characteristics that are most valued in a CMO
• Professional opinions on what areas are missing from the CMO market

As pharmaceutical businesses worldwide become more aware of the importance of meeting sustainability goals, it is inevitable that this will become a consideration when selecting a contract manufacturing organisation (CMO) or contract development and manufacturing organisation (CDMO). But it’s important to ensure that meeting sustainability goals when collaborating with external partners is genuine rather than just greenwashing.

That's why ahead of Pharma Contract Manufacturing 2024 we have collated exclusive insights on CMO Selection - Making Sustainability a Top Priority.

Access the infographic and dive into:

• The Top 5 considerations for sustainable CMO selection
• Key questions for the selection process
• Changing the culture strategy
• Examining your Scope 3 emissions
• Real-world examples of setting measurable targets
• Looking ahead: The big picture benefits

Download Mabion's case study to learn more about cell binding for biological drugs